Le Lézard
Classified in: Health, Science and technology
Subject: PLW

AiViva Biopharma Receives New Patent


NEWPORT BEACH, Calif., Aug. 17, 2022 /PRNewswire/ -- AiViva Biopharma, a clinical stage biopharmaceutical company has received patent US 11,400,089 on August 2, 2022. This patent is a method of use patent for sGC stimulator and multikinase inhibitors to prevent and/or treat fibrosis (thickening or scarring of tissue) associated with reproductive or digestive tract diseases. Fibrosis is involved in the pathogenesis of a number of diseases and/or disorders affecting the reproductive and digestive tracts in humans.

This patent adds to AiViva's 22 approved patents in the US, Canada, China, Japan, Korea, Australia, and Taiwan. To date, AiViva has filed over 63 patent applications worldwide.

"With these patents and proof of concept studies, it continues to secure our corporate position and development strategy to develop focal therapies for many diseases of significant unmet medical needs." said Diane Tang-Liu, PhD, CEO, President & Co-Founder.

About AiViva Biopharma

Please follow us at www.aiviva.com AiViva is a clinical stage biopharmaceutical company founded in 2015, with headquarters in Newport Beach, CA. AiViva is developing new therapeutics using innovative approaches, with proprietary technologies, including JELTM to address high unmet medical needs through focal therapies that target diseases of neovascularization, abnormal cell proliferation, and fibrosis.

SOURCE AiViva Biopharma


These press releases may also interest you

at 20:30
Tianma showcasing wide range of new display products and prototype technologies at Display Week 2024
Tianma, a leading global manufacturer of flat panel displays, is exhibiting a wide variety of new display technologies and solutions at Display Week 2024, Booth #516, San Jose, California, May 14-16. Demos include AMOLED, LTPS, Mini-LED,...

at 20:00
The Fight for Elderym Begins Today as Guild of Guardians Launches on iOS and Android
Immutable Games today announced that its flagship title, Guild of Guardians (GOG), is now available via Google Play and the Apple App Store. Developed in partnership with acclaimed studio, Mineloader, known for co-developing and working on some of...

at 19:35
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. announced today that Eisai has initiated the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for...

at 19:34
Andlauer Healthcare Group Announces Intention To Commence Substantial Issuer Bid
Andlauer Healthcare Group Inc. ("AHG" or the "Company") today announced that the Board has approved a substantial issuer bid (the "Offer") under which the Company will offer to purchase for cancellation up to 2,000,000 subordinate voting shares of...

at 19:00
UST to Train Over 25,000 Employees in Generative AI Technologies
UST, a leading digital transformation solutions company, has launched a groundbreaking new initiative to train over 25,000 of its employees globally in Generative AI (GenAI) and provide opportunities for career advancement. This ambitious program...

at 19:00
LG Display Unveils Newest Next-generation OLED Technologies at SID Display Week 2024
LG Display, the world's leading innovator of display technologies, announced today the unveiling of a large number of its next-generation OLED and cutting-edge display technologies at SID Display Week 2024 in San Jose, California from May 14-16....

More news about Science and technology...


News published on and distributed by: